“SGLT2 Inhibitors Associated with Lower Healthcare Costs and Utilization vs DPP4 Inhibitors in Japanese Type 2 Diabetes Patients with Higher BMI”

https://pubmed.ncbi.nlm.nih.gov/38112598

In a real-world analysis of Japanese patients with type 2 diabetes, those initiated on sodium-glucose cotransporter 2 inhibitors had lower healthcare resource utilization and costs compared to those on dipeptidyl peptidase-4 inhibitors, particularly among patients with higher body mass index.